Association between MDM2 SNP309 and endometrial cancer risk
A PRISMA-compliant meta-analysis

Xinwei Zou, MD, Yi Zhang, MD, Lin Zhang, MD, Jiaxi Li, MD, Chenjie Zhu, MD, Qiuhong Cheng, MD, Jinhua Zhou, PhD, Youguo Chen, PhD

Abstract

Background: Murine double minute 2 homolog (MDM2) plays an important role in the downregulation of P53 tumor suppressor gene. MDM2 inhibits P53 transcriptional activity and thereby results in accelerated tumor formation. Overexpression of MDM2 has been found in several cancer types including endometrial cancer. SNP309 is located in the promoter region of MDM2 and contributes to the overexpression of MDM2. The association between MDM2 SNP309 polymorphism and endometrial cancer risk has been investigated in several studies; however, the conclusion remains controversial.

Objectives: We performed the present meta-analysis to give a comprehensive conclusion of the association between MDM2 SNP309 polymorphism and endometrial cancer susceptibility.

Methods: We conducted a literature research on PubMed, Embase, Cochrane Library, OVID, Web of Science, Wan Fang, CNKI, and COVIP databases up to July 31, 2018. Newcastle–Ottawa scale was used to assess the quality of studies. We evaluated the strength of association by combining odds ratios (ORs) and 95% confidence intervals (CIs) in 5 different genetic models under a fixed-effect model or random-effect model. We further conducted subgroup analysis by ethnicity, source of control, histological type, clinical type, grade, and stage of tumor. Sensitivity analysis and publication bias were also performed.

Results: Nine eligible studies were finally included in our meta-analysis. We found MDM2 SNP309 polymorphism increased the risk of endometrial cancer under allele model (OR: 1.23, 95% CI: 1.06–1.41, P = .005), homozygote model (OR: 1.43, 95% CI: 1.13–1.81, P = .003) and recessive model (OR: 1.55, 95% CI: 1.17–2.04, P = .002). Subgroup analysis suggested a similar elevated risk in both Asians and Caucasians. We identified a strong association of enhanced susceptibility to endometrial cancer in endometrioid group (OR: 2.13, 95% CI: 1.28–3.54, P = .004) and Type I group (OR: 1.89, 95% CI: 1.25–2.86, P = .002) under dominant model. We identified no significant publication bias according to Egger’s test.

Conclusions: Our meta-analysis suggested that MDM2 SNP309 polymorphism increased the risk of endometrial cancer significantly, especially in endometrioid and Type I endometrial cancer, indicating MDM2 could serve as a potential diagnostic factor marker for endometrial cancer.

Abbreviations: CI = confidence interval, HB = hospital-based, HWE = Hardy–Weinberg equilibrium, MDM2 = murine double minute 2, NOS = Newcastle–Ottawa scale, ORs = odds ratios, PB = population-based, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RAF = risk allele frequency, SNP = single nucleotide polymorphism.

Keywords: endometrial cancer, MDM2, meta-analysis, polymorphism, SNP309

Editor: Qinhong Zhang

The study was designed by XZ, JZ, and YC. XZ, and YZ did the literature search, study quality assessment, and data extraction. XZ, YZ, LZ, and JL performed the statistical analysis and drafted the tables and figures. XZ wrote the first draft of this analysis, and YZ, CZ, and QC helped to finish the final version. All authors approved the conclusions of our study.

This work was financially supported by National Natural Science Foundation of China (No. 81672560, 81772773, 81302275), Jiangsu Provincial Medical Youth Talent (No. QNRC2016753), and The Project of Jiangsu Provincial Maternal and Child Health Association (No. FYX201709).

The authors have no conflicts of interest to disclose.

* Department of Obstetrics and Gynecology. † Department of Thoracic Surgery. The First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu, PR China.

Correspondence: Jinhua Zhou and Youguo Chen, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, 188 Shai Road, Suzhou City, Jiangsu 215006, PR China (e-mails: jinhua.zhou@suda.edu.cn; chenyouguo@suda.edu.cn).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2018) 97:49(e13273)

Received: 3 February 2018 / Accepted: 23 October 2018

http://dx.doi.org/10.1097/MD.0000000000013273
1. Introduction

Endometrial cancer is one of the most common gynecologic carcinoma worldwide.\textsuperscript{[1,2]} Its incidence rate has been increasing during last decades, especially in developed countries.\textsuperscript{[2]} The etiology of endometrial cancer remains unclear due to complex mechanisms of pathogenesis. It has been reported that environmental factors such as hormone exposure and obesity may contribute to the carcinogenesis of endometrial carcinoma.\textsuperscript{[3,4]} Genetic predisposition has also been confirmed to be involved in the etiology.\textsuperscript{[5,6]}

Murine double minute 2 homolog (MDM2) is located in chromosome 12q13-14 and plays a key role in the down-regulation of P53 tumor suppressor gene.\textsuperscript{[7]} P53 is a crucial component that regulates the cell-cycle arrest and apoptosis in response to DNA damage or oncogene expression. It was reported that MDM2 inhibited P53 transcriptional activity through ubiquitination and degradation, thereby resulting in accelerated tumor formation.\textsuperscript{[8]} Overexpression of MDM2 has been found in several cancers, including lung, breast, prostate, bladder, gastric, colorectal, hepatocellular, and endometrial cancer.\textsuperscript{[9–12]} A functional single nucleotide polymorphism located in 309bp downstream from intron 1 in the promoter region of MDM2 (a change from T to G) was identified and is referred to as SNP309.\textsuperscript{[17,13]} The G variant allele was found to enhance the affinity of MDM2 to SP1 transcription factor and leading to MDM2 overexpression.\textsuperscript{[15,16]} Several studies have also revealed that G allele of SNP309 is associated with an elevated susceptibility to cancer.\textsuperscript{[14–16]}

So far, the relationship between MDM2 SNP309 polymorphism and endometrial cancer risk has been investigated in several studies, but the conclusions remain inconsistent. Due to the relatively small sample size of each individual study and the conflict results, we performed the present meta-analysis with 9 eligible studies\textsuperscript{[17–25]} to give a more accurate and comprehensive estimation of the association between MDM2 SNP309 and the susceptibility to endometrial carcinoma.

2. Methods

We performed our meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).\textsuperscript{[26]}

2.1. Search strategy

We performed a comprehensive literature search for relevant studies in PubMed, Embase, Cochrane Library, OVID, Web of Science, Wan Fang, CNKI, and CQVIP databases up to July 31, 2018. We combined the following items in our search strategy: Polymorphism\textsuperscript{*} or SNP\textsuperscript{*} or mutant or mutation or variation; MDM 2 or MDM-2 or MDM2 or Mouse double minute 2 or Mouse double minute-2 or Mouse double minute2 or Murine double minute 2 or Murine double minute-2 or Murine double minute2; (Endometrial or Endometrium) and (cancer\textsuperscript{*} or neoplasm\textsuperscript{*} or carcinoma\textsuperscript{*}). Furthermore, references of previous articles were manually searched for potential studies.

2.2. Inclusion and exclusion criteria

The inclusion criteria were: studies with case–control or cohort designs; studies investigating the potential association between MDM2 SNP309 polymorphism and endometrial cancer risk; studies with sufficient original data to calculate odds ratios (ORs) and 95% confidence interval (95% CI). When overlapping data appeared in multiple publications, only the study containing largest sample size was included in our meta-analysis.

The exclusion criteria were: reviews, letters, meta-analysis, case reports, meeting abstracts, articles without controls, and articles with different designs.

2.3. Data extraction and quality assessment

Two authors (XZ and YZ) individually reviewed the eligible articles and extracted all useful data from them. Conflicts among the extraction were resolved by discussion with a third investigator (YC). The information extracted from each study was as follows: the last name of the first author, publication year, country and ethnicity of the participants, number of cases and controls, source of controls, and genotypes distribution. We evaluated the quality of studies according to 9-point Newcastle–Ottawa scale (NOS).\textsuperscript{[27]}

2.4. Statistical analysis

Hardy–Weinberg equilibrium (HWE) tests were conducted in each involved study to assess the deviation of genotype distribution from population. The strength of association between MDM2 SNP309 polymorphism and endometrial cancer risk was measured by combined ORs with 95%CI under fixed-effect model or random-effect model according to the heterogeneity among studies. We quantified the heterogeneity by $I^2$ test which ranges from 0% to 100% to represent the degree of heterogeneity. It indicated significant heterogeneity when $I^2 > 50\%$ and a random-effect model (Der Simonian and Laird method) should be adopted for pooled ORs,\textsuperscript{[28]} otherwise the fixed-effect model (Mantel–Haenszel method) was used.\textsuperscript{[29]} To investigate the origin of heterogeneity, we further performed subgroup analysis stratified by ethnicity, source of control, histological type, clinical type, grade and stage of tumor. The overall and subgroup analysis categorized by ethnicity and source of control were performed under five genetic models: allele model (G vs T), homozygote model (GG vs TT), heterozygote model (GT vs TT), dominant model (GG+GT vs TT), and recessive model (GG vs GT+TT), respectively. However, only dominant model was used in the subgroup analysis stratified by histological type, clinical type, grade and stage of tumor because the majority of included researches only provided the data of GG+GT versus TT for these subgroups. Sensitivity analysis was also performed by combining ORs with the removal of each single involved study to investigate the potential subversion of the results. Egger’s test and Begg’s funnel plot were used to estimate publication bias. $P < .05$ was considered as identification of statistically significant bias of publication.\textsuperscript{[30]} All the data were processed by STATA version12 (Stata Corporation, College Station, TX).

2.5. Ethical approval

Since meta-analysis belonged to secondary analysis based on the studies published previously, the patients’ informed consent and the ethical approval were not necessary.

3. Results

3.1. Study characteristics

We identified 171 records in total in primary search from 8 databases with our criterion. There remained 139 studies for screening after the duplicated records were eliminated and 124
studies were excluded after skimming the titles and abstracts. Among the 13 studies read by full text, 6 were excluded because 2 offered overlapping data, 2 discussed other genetic locus of MDM2, and 2 designed differently. The intact procedures of inclusion and exclusion are shown in Figure 1. Eventually, there were 9 studies containing 3535 cases and 6476 controls eligible for our meta-analysis. One of them involved data from 2 different ethnic groups, so we treated it as 2 separate groups. Table 1 demonstrates the main characteristics of the studies involved. The eligible researches were performed in different
Table 1
Characteristics of the studies included for meta-analysis.

| First author       | Year | Country | Ethnicity | Source of controls | Sample size | HWE test |
|--------------------|------|---------|-----------|--------------------|-------------|----------|
| Walsh[17]          | 2007 | America | Mixed     | HB                 | 73          | 0.65     |
| Terry-NHS[18]      | 2008 | America | Caucasian | PB                 | 394         | 0.64     |
| Terry-WhS[16]      | 2008 | America | Caucasian | PB                 | 122         | 0.18     |
| Ashton[19]         | 2009 | Australia | Caucasian | PB                 | 191         | 0.49     |
| Ueda[20]           | 2009 | Japan   | Asian     | HB                 | 119         | 0.02     |
| Knappskog[21]      | 2012 | Norway  | Caucasian | HB                 | 910         | 0.41     |
| Zajac[22]          | 2012 | Poland  | Caucasian | PB                 | 152         | 0.70     |
| Yoneda[23]         | 2013 | Japan   | Asian     | PB                 | 125         | 0.01     |
| Okamoto[24]        | 2015 | Japan   | Asian     | PB                 | 45          | 0.63     |
| Gansmo[25]         | 2017 | Norway  | Caucasian | PB                 | 1404        | 0.80     |

Case–control design was used in all the included studies.
HWE = Hardy–Weinberg equilibrium, HB = hospital-based, PB = population-based, year = publication year.

Table 2
The results of Newcastle–Ottawa scale.

| First author       | Selection | Comparability | Exposure |
|--------------------|-----------|---------------|----------|
| Walsh[17]          | ★★★★★    | ★★★          | ★★★★★   |
| Terry[18]          | ★★★★☆☆   | ★★★          | ★★★★★   |
| Terry-WhS[16]      | ★★★★☆☆   | ★★★          | ★★★★★   |
| Ashton[19]         | ★★★★☆☆   | ★★★          | ★★★★★   |
| Ueda[20]           | ★★★★☆☆   | ★★★          | ★★★★★   |
| Knappskog[21]      | ★★★★☆☆   | ★★★          | ★★★★★   |
| Zajac[22]          | ★★★★☆☆   | ★★★          | ★★★★★   |
| Yoneda[23]         | ★★★★☆☆   | ★★★          | ★★★★★   |
| Okamoto[24]        | ★★★★☆☆   | ★★★          | ★★★★★   |
| Gansmo[25]         | ★★★★★☆☆  | ★★★          | ★★★★★   |

Table 3
SNP309 polymorphism of MDM2 genotype distribution and allele frequency in cases and controls.

| First author       | Cases | Controls | Allele frequency (N, %) |
|--------------------|-------|----------|------------------------|
|                    | Genotype (N) | |                        |
|                    | GG     | TG      | TT                     | GG     | TG      | TT                     |
| Walsh[17]          | 73     | 18      | 27                    | 79     | 9       | 38                    |
| Terry-NHS[18]      | 394    | 63      | 162                  | 169    | 948     | 95                   | 420    | 433     |
| Terry-WhS[16]      | 122    | 21      | 54                   | 47     | 368     | 50                   | 155    | 163     |
| Ashton[19]         | 191    | 29      | 84                   | 78     | 291     | 37                   | 126    | 128     |
| Ueda[20]           | 119    | 39      | 54                   | 26     | 108     | 22                   | 66     | 20      |
| Knappskog[21]      | 910    | 123     | 426                 | 361    | 2465    | 300                  | 1093   | 1072    |
| Zajac[22]          | 152    | 96      | 30                   | 24     | 100     | 28                   | 48     | 24      |
| Yoneda[23]         | 125    | 34      | 61                   | 30     | 200     | 40                   | 98     | 62      |
| Okamoto[24]        | 45     | 10      | 21                   | 14     | 45      | 9                    | 24     | 12      |
| Gansmo[25]         | 1404   | 186     | 642                  | 576    | 1872    | 254                  | 878    | 740     |

Case–control design was used in all the included studies.
MDM2 = murine double minute 2, RAF = risk allele frequency, risk allele = G allele, SNP = single nucleotide polymorphism.

3.2. Quantitative synthesis

In overall analysis, the results indicated that MDM2 SNP309 polymorphism significantly increased the risk of endometrial carcinoma under allele model (OR: 1.23, 95% CI: 1.06–1.41, P = 0.005, I² = 72.2%, P_heterogeneity = 0.00), homozygote model (OR: 1.43, 95% CI: 1.13–1.81, P = 0.003, I² = 56.4%, P_heterogeneity = 0.01) and recessive model (OR: 1.55, 95% CI: 1.17–2.04, P = 0.002, I² = 75.5%, P_heterogeneity = 0.00) (Fig. 2). However, no statistical association was identified under heterozygote model (OR: 1.02, 95% CI: 0.93–1.12, P = 0.69, I² = 3.6%, P_heterogeneity = 0.41) and dominant model (OR: 1.08, 95% CI: 0.99–1.17, P = 0.09, I² = 6.7%, P_heterogeneity = 0.38) (Fig. 2).

We further performed subgroup analysis to investigate the source of high heterogeneity among studies. In subgroup analysis stratified by ethnicity, significant association of an elevated cancer risk was found in Asians under recessive model (OR: 1.58, 95% CI: 1.10–2.29, P = 0.02, I² = 0.0%, P_heterogeneity = 0.67) and in Caucasians under allele model (OR: 1.23, 95% CI: 1.03–1.47, P = 0.02, I² = 83.2%, P_heterogeneity = 0.00), homozygote model (OR: 1.40, 95% CI: 1.05–1.88, P = 0.02, I² = 71.5%, P_heterogeneity = 0.00) and recessive model (OR: 1.49, 95% CI: 1.05–2.13, P = 0.03, I² = 84.4%, P_heterogeneity = 0.00). When classified according to source of control, the significantly heightened risk was only identified in hospital-based group under homozygote model (OR: 1.65, 95%
CI: 1.04–2.63, \( P = .04, I^2 = 56.5\%, P_{\text{heterogeneity}} = .06 \), dominant model (OR: 1.16, 95% CI: 1.01–1.33, \( P = .04, I^2 = 0.0\%, P_{\text{heterogeneity}} = .54 \)) and recessive model (OR: 1.97, 95% CI: 1.05–3.70, \( P = .04, I^2 = 83.9\%, P_{\text{heterogeneity}} = .00 \)), but not in population-based group. Furthermore, we attempted to conduct stratified analysis by various clinicopathological characteristics.
including histological and clinical type, grade and stage of endometrial cancer. We accidentally found a stronger correlation with higher ORs in endometrioid (OR: 2.13, 95% CI: 1.28–3.54, \( P = .004, I^2 = 0.0\% \), \( P_{\text{heterogeneity}} = .36 \) under dominant model, but no association was found in nonendometriod and Type II groups. In subgroup analysis by grade, there found no statistical relationship between
all three grades of endometrial cancer and MDM2 SNP309 polymorphism. But when categorized by stage, we identified a distinct increased risk with ORs even higher than endometrioid and Type I group in stage I and III endometrial cancer. The complete results of subgroup analysis are shown in Table 4.

3.3. Sensitivity analysis
We performed sensitivity analysis to investigate whether the absence of each study will alter the result of our meta-analysis. As Figure 3 indicates, no results were subverted when each study was excluded individually, which manifested the stability and reliability of our conclusion (Fig. 3).

3.4. Publication bias
Egger’s test and Begg’s funnel plot were conducted to evaluate the publication bias. The Begg’s funnel plot appeared to be symmetrical visually (Fig. 4), which suggested no evidence of publication bias (Egger’s test: $P = .06$).

4. Discussion
So far, investigation of association between MDM2 SNP309 and risk of endometrial cancer has been reported in several researches, but the results remain controversial. Among all included studies, 4 studies revealed an increased risk of MDM2 SNP309 polymorphism in endometrial cancer,\(^{[17,19,20,22]}\) 2 studies suggested no statistical significance,\(^{[19,23]}\) one reported a suspicious relationship,\(^{[21]}\) and the rest 2 did not mention the association between them in their articles.\(^{[24,25]}\) Due to the conflicting results from the studies with relatively small sample size, we conducted the present meta-analysis to seek a comprehensive conclusion.

Nine included studies with 10 groups of data were consolidated to seek the connection of MDM2 SNP309 gene polymorphism and endometrial cancer susceptibility. One research conducted by Nunobiki et al.\(^{[31]}\) from Japan was excluded because the data is overlapped with another study and the sample size is smaller than it. The overall analysis revealed that MDM2 SNP309 significantly enhanced the risk of endometrial cancer. MDM2 is a negative regulator of P53 and plays a crucial role in P53 tumor suppressor pathway.\(^{[32]}\) Previous studies showed that MDM2 could bind to P53 protein directly to inhibit its activity via ubiquitination and degradation.\(^{[33]}\) The overexpression of MDM2 was reported as a carcinogenic factor by reduction of P53 levels, which attenuated P53 apoptosis response to DNA damage and other cellular stresses, and subsequently resulted in accumulation of genetic errors, leading to accelerated cancer formation.\(^{[13,34–38]}\) MDM2 was also reported to facilitate tumor growth in a P53-independent way.\(^{[39]}\) The polymorphism of SNP309, which located in MDM2 promoter region, was reported to upregulate the MDM2 expression.\(^{[27]}\) This may account for the increased risk of endometrial cancer caused by MDM2 SNP309 polymorphism. Subgroup analysis was performed to investigate the source of interstudy heterogeneity. The subgroup analysis by ethnicity indicated an elevated susceptibility to endometrial carcinoma in Asians under recessive model and in Caucasians under allele, homozygote and recessive model, which means MDM2 SNP309 polymorphism may contribute to endometrial cancer carcino-
genesis in both ethnic populations, but the association is stronger in Caucasians than in Asians. Since cancer is a disease with complicated multigenetic effect, the similarity and difference between races may be responsible for the results. When stratified by source of control, significant association of similar enhanced susceptibility to endometrial cancer could only be found in hospital-based group. This result may reveal potential selection bias among these studies when recruiting participants for matched control groups.

We further performed subgroup analysis categorized by several clinicopathological characteristics including histological and clinical type, grade, and stage of endometrial cancer. We identified a strong association of increased risk of endometrial cancer in endometrioid group and Type I group. Endometrial cancer is classified into 2 clinical types: Type I and II. Type I is estrogen-dependent endometrial cancer and belongs to endometrioid type histologically. It is associated with endometrial hyperplasia. Estrogen receptors are commonly expressed in Type I tumor cells. Type II endometrial carcinoma is estrogen-independent and encompasses nonendometrioid type. It is related to atrophic endometrium and the tumor cells scarcely express estrogen receptors.[40,41] Previous researches indicated that MDM2 overexpression is strongly concerned with estrogen receptor.[34,42] The expression of MDM2 is mediated through the interaction of estrogen receptor with a promoter region of MDM2 where SNP309 located.[43] In addition, it is reported that the GG genotype of SNP309 increases the affinity of MDM2 promoter to the transcription factor SP1.[7] SP1 is known as a co-transcriptional activator of estrogen receptor[44] and contributes to estrogen-mediated gene transcription. [45,46] Therefore, MDM2 SNP309 polymorphism may enhance the susceptibility to estrogen-related Type I endometrial carcinoma, which is in accordance with the result of our subgroup analysis. No statistical association was found between all three grades of

### Table 4
Subgroup analyses of association between MDM2 SNP309 polymorphism and endometrial cancer.

| Subgroup          | Number | ORs  | 95% CI    | P       | \( \hat{\beta} \) (%) | Pooling model |
|-------------------|--------|------|-----------|---------|------------------------|---------------|
| **Source of control** |        |      |           |         |                        |               |
| Allele model      |        |      |           |         |                        |               |
| HB                | 5      | 1.37 | (0.98,1.92) | .06     | 79.7                   | Random-effects model |
| PB                | 5      | 1.13 | (0.98,1.30) | .09     | 55.3                   | Random-effects model |
| Homozygote model  |        |      |           |         |                        |               |
| HB                | 5      | 1.65 | (1.04,2.63) | .04     | 56.5                   | Random-effects model |
| PB                | 5      | 1.33 | (0.98,1.81) | .07     | 60.2                   | Random-effects model |
| Heterozygote model|        |      |           |         |                        |               |
| HB                | 5      | 1.07 | (0.92,1.24) | .40     | 37.4                   | Fixed-effects model |
| PB                | 5      | 0.99 | (0.88,1.11) | .89     | 0.0                    | Fixed-effects model |
| Dominant model    |        |      |           |         |                        |               |
| HB                | 5      | 1.16 | (1.01,1.33) | .04     | 0.0                    | Fixed-effects model |
| PB                | 5      | 1.03 | (0.93,1.15) | .58     | 18.1                   | Fixed-effects model |
| Recessive model   |        |      |           |         |                        |               |
| HB                | 5      | 1.97 | (1.05,3.70) | .04     | 83.9                   | Random-effects model |
| PB                | 5      | 1.29 | (0.99,1.67) | .06     | 55.2                   | Random-effects model |
| **Ethnicity**     |        |      |           |         |                        |               |
| Allele model      |        |      |           |         |                        |               |
| Asian             | 3      | 1.22 | (0.98,1.53) | .08     | 0.0                    | Fixed-effects model |
| Caucasian         | 6      | 1.23 | (1.03,1.47) | .02     | 83.2                   | Random-effects model |
| Mixed             | 1      | 1.38 | (0.87,2.20) | .17     | —                      | —              |
| Homozygote model  |        |      |           |         |                        |               |
| Asian             | 3      | 1.47 | (0.94,2.32) | .09     | 0.0                    | Fixed-effects model |
| Caucasian         | 6      | 1.40 | (1.05,1.88) | .02     | 71.5                   | Random-effects model |
| Mixed             | 1      | 2.29 | (0.89,5.90) | .09     | —                      | —              |
| Heterozygote model|        |      |           |         |                        |               |
| Asian             | 3      | 0.94 | (0.64,1.38) | .74     | 29.1                   | Fixed-effects model |
| Caucasian         | 6      | 1.03 | (0.94,1.13) | .56     | 15.4                   | Fixed-effects model |
| Mixed             | 1      | 0.81 | (0.40,1.65) | .56     | —                      | —              |
| Dominant model    |        |      |           |         |                        |               |
| Asian             | 3      | 1.00 | (0.76,1.57) | .64     | 11.3                   | Fixed-effects model |
| Caucasian         | 6      | 1.08 | (0.98,1.18) | .11     | 32.3                   | Fixed-effects model |
| Mixed             | 1      | 1.09 | (0.57,2.10) | .79     | —                      | —              |
| Recessive model   |        |      |           |         |                        |               |
| Asian             | 3      | 1.58 | (1.10,2.29) | .02     | 0.0                    | Fixed-effects model |
| Caucasian         | 6      | 1.49 | (1.05,2.13) | .03     | 84.4                   | Random-effects model |
| Mixed             | 1      | 2.55 | (1.06,6.10) | .04     | —                      | —              |
| **Histological type** |    |      |           |         |                        |               |
| Dominant model    |        |      |           |         |                        |               |
| Endometrioid      | 2      | 2.13 | (1.28,3.54) | .004    | 0.0                    | Fixed-effects model |
| Nonendometrioid   | 2      | 1.94 | (0.35,10.87)| .45     | 62.1                   | Random-effects model |
| **Clinical type** |        |      |           |         |                        |               |
| Dominant model    |        |      |           |         |                        |               |
| Type I            | 2      | 1.89 | (1.25,2.86) | .002    | 0.0                    | Fixed-effects model |
| Type II           | 2      | 0.90 | (0.41,1.96) | .79     | 0.0                    | Fixed-effects model |
| **Grade**         |        |      |           |         |                        |               |
| Dominant model    |        |      |           |         |                        |               |
| Grade 1           | 2      | 1.79 | (0.92,3.50) | .09     | 0.0                    | Fixed-effects model |
| Grade 2           | 2      | 1.84 | (0.96,3.52) | .07     | 0.0                    | Fixed-effects model |
| Grade 3           | 2      | 2.28 | (0.63,8.28)| .21     | 62.6                   | Random-effects model |
| **Stage**         |        |      |           |         |                        |               |
| Dominant model    |        |      |           |         |                        |               |
| I                 | 2      | 4.40 | (2.60,7.45)| <3.001  | 49.8                   | Fixed-effects model |
| II                | 2      | 3.36 | (0.93,12.06)| .06     | 56.3                   | Random-effects model |
| III               | 2      | 4.31 | (1.06,17.18)| .04     | 56.1                   | Random-effects model |
| IV                | 1      | 1.11 | (0.12,10.10)| .93     | —                      | —              |

95% CI = 95% confidence interval, HB = hospital based, ORs = odds ratios, PB = population based, SNP = single nucleotide polymorphism.
endometrial cancer and MDM2 SNP309 polymorphism. When stratified by stage of tumor, our analysis revealed a markedly elevated risk of endometrial cancer in stage I and III group, but not in stage II and IV. Small sample size may be responsible for the dubious result because only 2 studies provided the data of genotype concerned with different stage of carcinoma containing 129 stage I, 42 stage II, 46 stage III and 8 stage IV patients in total. It is noteworthy that the results of the subgroup analysis categorized by various clinicopathological characteristics should be concluded and generalized with caution considering the limited number of relevant studies.

Although one study included in our analysis deviated from HWE in controls, the conclusions were not subverted when removing the study during sensitivity analysis. Also, we recognized no publication bias in our meta-analysis.

Several limitations of our meta-analysis should be admitted. Firstly, one study is not consistent with the HWE in controls; despite the conclusions did not alter after it was excluded.
Secondly, data of Africans were not involved because no involved studies mentioned it, which may lead to selection bias. Thirdly, we did not perform subgroup analysis by age, obesity, menstrual status, hypertension history, diabetes history and family history because of insufficient data. Finally, interaction of several gene polymorphisms may also influence endometrial cancer risk, which was not involved in our analysis.

Gene targeting therapy has played an important role in the treatment of several cancers such as lung cancer, breast cancer, chronic myeloid leukemia and so on, but it is still not widely conducted in gynecological tumor. The very first step is to identify the association between gene mutation and endometrial cancer susceptibility, as well as the mechanism of it. Our meta-analysis showed that MDM2 SNP309 polymorphism increased the risk of endometrial cancer significantly both in Asians and Caucasians, but the strength of association may be stronger in Caucasians than in Asians. Also, we identified that SNP309 polymorphism elevated the Type I and endometrioid type endometrial carcinoma significantly. Our result revealed that MDM2 SNP309 polymorphism could serve as a potential prognostic marker for endometrial cancer and may further possibly guide genetic targeted therapy and even prevention strategies. Still, further evidences from future studies with standardized genotyping methods, multiple populations and pathological types are needed to corroborate our conclusions and provide a more comprehensive and precise understanding of association between MDM2 SNP309 polymorphism and endometrial cancer.

Author contributions

Conceptualization: Xinwei Zou, Jinhua Zhou, Youguo Chen.

Data curation: Xinwei Zou, Yi Zhang, Lin Zhang, Jiaxi Li.

Formal analysis: Xinwei Zou, Yi Zhang, Lin Zhang, Jiaxi Li.

Funding acquisition: Jinhua Zhou, Youguo Chen.

Investigation: Xinwei Zou, Yi Zhang, Lin Zhang, Jiaxi Li, Chenjie Zhu, Quihong Cheng.

Methodology: Xinwei Zou, Yi Zhang, Youguo Chen.

Resources: Xinwei Zou, Yi Zhang, Youguo Chen.

Software: Xinwei Zou, Yi Zhang.

Supervision: Jinhua Zhou, Youguo Chen.

Validation: Jinhua Zhou, Youguo Chen.

Visualization: Xinwei Zou, Yi Zhang, Lin Zhang, Jiaxi Li.

Writing – original draft: Xinwei Zou.

Writing – review & editing: Chenjie Zhu, Quihong Cheng.

References

[1] Amant F, Moorman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491–505.

[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.

[3] Lane D. Obesity and gynaecological cancer. Menopause Int 2008;14:33–7.

[4] Tinelli A, Vergara D, Martinezagoitia R, et al. Hormonal carcinogenesis and socio-biological development factors in endometrial cancer: a clinical review. Acta Obstet Gynecol Scand 2008;87:1101–13.

[5] Wang Y, Cui M, Zheng L. Genetic polymorphisms in the estrogen receptor-alpha gene and the risk of endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand 2012;91:911–6.

[6] Zhou X, Gu Y, Wang DN, et al. Eight functional polymorphisms in the estrogen receptor gene and endometrial cancer risk: a meta-analysis. PLoS One 2013;8:e60851.

[7] Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591–602.

[8] Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors 2005;23:83–92.

[9] Monand J, Jung D, Wizkynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3433–9.

[10] Oliner JD, Kimzler KW, Melzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80–3.

[11] Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27–41.

[12] Wu X, Han D, Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis. J Genet Genomics 2011;38:341–50.

[13] Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481–4.

[14] Althuopuro P, Ylihaukko-Oja SK, Koskinnen WJ, et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:948–49.

[15] Bogueard G, Baert-Desurmont S, Tournier L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006;43:531–3.

[16] Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582–7.

[17] Walsh CS, Miller CW, Kang B, et al. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007;104:660–6.

[18] Terry K, McGrath M, Lee IM, et al. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:983–6.

[19] Ashton KA, Pietro A, Otton G, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 2009;113:109–14.

[20] Ueda M, Yamamoto M, Nunoobiki O, et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell 2009;22:49–54.

[21] Knappskog S, Tirov J, Marciziovicz J, et al. SNP285C modulates oestrogen receptorSp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer 2012;48:1988–96.

[22] Zajac A, Stachowiak G, Pertynski T, et al. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. Polish J Pathol 2012;63:278–83.

[23] Yoneda T, Kuboyama A, Kato K, et al. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. Oncol Rep 2013;30:25–34.

[24] Okamoto K, Tsunematsu R, Tahira T, et al. SNP55, a new functional homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Gynecol Oncol 2009;113:109–14.

[25] Gansmo LB, Bjornset M, Halle MK, et al. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial cancer. J Epidemiol 2010;25:603–6.

[26] Nunobiki O, Ueda M, Yamamoto M, et al. Polymorphisms of p53 codon 72 and MDM2 combined are associated with high grade endometrial cancer. J Med Genet 2005;42:948–49.

[27] Lane G. Obesity and gynaecological cancer. Menopause Int 2008;14:33–7.

[28] Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2-mediated p53 polyubiquitination and degradation. Cell 2009;138:101–8.

[29] Bond GL, Hirshfield KM, Kirchhoff T, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.

[30] Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[31] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.

[32] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.

[33] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[34] Nunoobiki O, Ueda M, Yamamoto M, et al. Polymorphisms of p53 codon 72 and MDM2 promoter polymorphism and the risk of endometrial cancer. Hum Cell 2009;22:101–6.

[35] Wu H, Leng RP, UEB4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 2011;10:1912–5.

[36] Poyurovsky MV, Katz G, Lapteroko O, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 2010;17:982–9.

[37] Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5304–10.
[35] Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296–9.
[36] Lind H, Zienolddiny S, Ekstrom PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;119:718–21.
[37] Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002;12:53–9.
[38] Sanchez-Carbayo M, Socci ND, Kirchoff T, et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 2007;13:3215–20.
[39] Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 2005;5:9–20.
[40] Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009;16:8–13.
[41] Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72–87.
[42] Phelps M, Darley M, Primrose JN, et al. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res 2003;63:2616–23.
[43] Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 2003;23:5867–81.
[44] Khan S, Abdelrahim M, Samudio I, et al. Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. Endocrinology 2003;144:2323–35.
[45] Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001;62:231–52.
[46] Schultz JR, Petz LN, Nardulli AM. Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. J Biol Chem 2005;280:347–54.